|
|
![](https://content.app-us1.com/cdn-cgi/image/dpr=2,fit=scale-down,format=auto,onerror=redirect,width=650/Mgo01/2024/01/31/e54bdf7a-f3e1-47d8-b21d-f2a17c017afb.png) |
Hi ,
|
Latest Videos From SynBioBeta 2024:
|
The Molecular Engines of Metabolism: Drew Berry presented the molecular mechanisms that power your cells and tissues, converting food and air into the flow of chemical energy that makes your body alive. Exploiting the incredible advances in video game technology, vast molecular landscapes can be generated upon a foundation of scientific research. Enabling interactive exploration of dynamic molecular biology in ultra-high resolution detail, accessible and illuminating science education delivered via student mobile technology.
Navigating the Investment Ecosystem: De-risking SynBio Ventures for Trend-Savvy Investors. In this dynamic session, we merge the foresight of investment trends with the strategic insight required to de-risk synthetic biology ventures. From understanding the intricacies of regulatory landscapes to mastering the art of communicating value propositions, this session promises a deep dive into how startups can align with investor expectations and navigate the complexities of capital acquisition in a landscape ripe with opportunity and challenge.
|
|
Discover how synthetic biology transforms industries such as healthcare, food, agriculture, environment, consumer goods, chemicals, materials, and more. Our flagship conference showcases the latest breakthroughs and trends in the field. Join us at SynBioBeta, May 5-8, 2025, and be part of the bio revolution! Register before conference pass pricing increases Friday, July 26.
|
|
|
|
|
|
|
At SynBioBeta, we are passionate about harnessing the power of biology to create transformative solutions for a better world. We can help you reach the full spectrum of synthetic biology professionals across a suite of media platforms. Download our 2024-2025 Media Kit
|
Insights:
|
|
Industry News:
|
Eligo Bioscience Achieves Breakthrough in In Vivo Bacterial Genome Editing: Published in the journal Nature, Eligo's work demonstrates for the first time the ability to precisely and efficiently edit the genomes of bacteria directly within the gut, achieving nearly 100% efficiency without disturbing surrounding microbial communities.
Harnessing Bacteriophage as a New Weapon Against Acute GVHD: New research uncovers the potential of endolysin enzyme in combating multidrug-resistant infections in allo-HCT patients.
Aspect Biosystems Secures $72.75 Million Government Investment to Advance Bioprinted Tissue Therapeutics. Aspect Biosystems is at the forefront of bioprinted tissue therapeutics, developing treatments designed to replace, repair, or supplement biological functions in the body.
Briefly Bio Launches to Tackle Reproducibility Crisis in Science: With this launch, Briefly Bio has also secured a $1.2 million pre-seed funding round led by Compound VC, with participation from NP-Hard, Tiny VC, and various angel investors from the tech and biotech sectors.
Syngenta and Ginkgo Bioworks Forge New Collaboration to Fast-Track Biological Solutions: This partnership marks a significant step forward in developing sustainable agricultural solutions, combining Syngenta's innovation in crop protection with Ginkgo's cutting-edge capabilities in biological engineering.
bitBiome Welcomes Industry Veteran John Nicols as Strategic Advisor to Propel Enzyme Product Development: John Nicols is also our Track Chair for the 2025
SynBioBeta Conference for Chemicals and Materials.
|
|
John Nicols speaking at SynBioBeta.
|
Additional Industry News:
|
Regards
Jeff
Jeffrey S. Buguliskis, PhD
Director of Content, SynBioBeta
|
Who's hiring?
|
|
|
|
|
|
|
|